Dizal Pharmaceutical Co., Ltd (Ticker: 688192) is a clinical stage, biopharmaceutical company. At Dizal we aspire to discover and develop differentiated therapeutics for the treatment of cancer and immunological diseases. Building on our extensive expertise in translational science and molecular design, we have established an internationally competitive portfolio with two leading assets at global pivotal studies.